BerGenBio ASA (BRRGF)
USD 2.5
(0.0%)
USD 2.5
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.6 Million USD | -42.3% |
| 2022 | 7.97 Million USD | 6.97% |
| 2021 | 7.45 Million USD | -6.11% |
| 2020 | 7.93 Million USD | 37.8% |
| 2019 | 5.76 Million USD | 20.07% |
| 2018 | 4.79 Million USD | -27.76% |
| 2017 | 6.64 Million USD | 45.5% |
| 2016 | 4.56 Million USD | 34.82% |
| 2015 | 3.38 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.89 Million USD | -10.13% |
| 2024 Q2 | 4.04 Million USD | 2.6% |
| 2023 Q1 | 6.42 Million USD | -19.46% |
| 2023 Q2 | 4.87 Million USD | -24.06% |
| 2023 FY | 4.6 Million USD | -42.3% |
| 2023 Q3 | 2.5 Million USD | -48.6% |
| 2023 Q4 | 4.6 Million USD | 83.51% |
| 2022 Q2 | 8.27 Million USD | 0.46% |
| 2022 FY | 7.97 Million USD | 6.97% |
| 2022 Q4 | 7.97 Million USD | 22.94% |
| 2022 Q3 | 6.48 Million USD | -21.62% |
| 2022 Q1 | 8.23 Million USD | 10.52% |
| 2021 Q1 | 8.66 Million USD | 0.0% |
| 2021 Q4 | 7.45 Million USD | 0.59% |
| 2021 Q3 | 7.4 Million USD | -8.76% |
| 2021 Q2 | 8.12 Million USD | -6.24% |
| 2021 FY | 7.45 Million USD | -6.11% |
| 2020 FY | 7.93 Million USD | 37.8% |
| 2019 FY | 5.76 Million USD | 20.07% |
| 2018 FY | 4.79 Million USD | -27.76% |
| 2017 FY | 6.64 Million USD | 45.5% |
| 2016 FY | 4.56 Million USD | 34.82% |
| 2015 FY | 3.38 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 91.37% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 51.989% |
| SQZ Biotechnologies Company | 50.03 Million USD | 90.806% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 93.652% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 92.205% |
| Mesoblast Limited | 188.44 Million USD | 97.559% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -19.446% |
| Genus plc | 485 Million USD | 99.051% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 21.262% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -82.821% |
| Marizyme, Inc. | 26.67 Million USD | 82.754% |
| ContraFect Corporation | 32.53 Million USD | 85.858% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -21.063% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -132.189% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -20.188% |
| Intellipharmaceutics International Inc. | 12 Million USD | 61.691% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 60.942% |
| MultiCell Technologies, Inc. | 1617.67 USD | -284283.218% |
| Accustem Sciences Inc. | 1.07 Million USD | -326.262% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 94.058% |
| EV Biologics, Inc. | 2.11 Million USD | -117.505% |
| Q BioMed Inc. | 8.13 Million USD | 43.435% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 94.453% |
| Neon Bloom, Inc. | 1.22 Million USD | -275.17% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 10.603% |
| Biomind Labs Inc. | 1.49 Million USD | -206.976% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 98.115% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 75.003% |
| Skye Bioscience, Inc. | 14.07 Million USD | 67.309% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -128.86% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3137.54% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 51.401% |
| IMV Inc. | 37.93 Million USD | 87.872% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2187.427% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 19.935% |
| GB Sciences, Inc. | 5.41 Million USD | 15.084% |
| Alpha Cognition Inc. | 7.16 Million USD | 35.792% |
| HST Global, Inc. | 593.59 Thousand USD | -675.006% |
| CSL Limited | 18.62 Billion USD | 99.975% |
| Halberd Corporation | 728.71 Thousand USD | -531.297% |
| Enzolytics Inc. | 365.26 Million USD | 98.741% |
| Resverlogix Corp. | 67.39 Million USD | 93.174% |
| Affymax, Inc. | 8.87 Million USD | 48.141% |
| SYBLEU INC | 681.41 Thousand USD | -575.124% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -448.492% |
| argenx SE | 444.95 Million USD | 98.966% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 93.86% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -168.4% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 61.351% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -25.516% |
| AVAX Technologies, Inc. | 3.99 Million USD | -15.19% |
| Zenith Capital Corp. | 27.56 Thousand USD | -16586.793% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.653% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1827.637% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -23.192% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -575.698% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.125% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 49.123% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -6773.526% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -220.839% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 90.848% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -69.653% |
| BioStem Technologies, Inc. | 15.9 Million USD | 71.075% |
| ONE Bio Corp. | 27.49 Million USD | 83.269% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -889.97% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -16669.518% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -265.344% |
| Agentix Corp. | 2.51 Million USD | -83.242% |
| LadRx Corporation | 2.2 Million USD | -109.058% |
| Cell Source, Inc. | 15.8 Million USD | 70.896% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -10192.603% |
| Regen BioPharma, Inc. | 5.45 Million USD | 15.707% |
| Regen BioPharma, Inc. | 5.45 Million USD | 15.707% |
| NovAccess Global Inc. | 7.86 Million USD | 41.476% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 81.41% |
| Itoco Inc. | 1.65 Million USD | -178.28% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -124.238% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 23.948% |
| Kadimastem Ltd | 3.5 Million USD | -31.257% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -991.255% |
| CytoDyn Inc. | 127.89 Million USD | 96.403% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -10905.962% |
| Mobile Lads Corp. | 1.31 Million USD | -250.239% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -193.696% |
| Qrons Inc. | 1.48 Million USD | -209.017% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 58.35% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -468.795% |
| Rebus Holdings, Inc. | 5.24 Million USD | 12.24% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 24.607% |
| International Stem Cell Corporation | 5.27 Million USD | 12.822% |
| Bioxytran, Inc. | 3.24 Million USD | -41.572% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -635.11% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 0.363% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 88.778% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 79.338% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -127.136% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 16.021% |
| Neutra Corp. | 973.52 Thousand USD | -372.547% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 84.145% |
| PureTech Health plc | 125.58 Million USD | 96.337% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -22.444% |
| IXICO plc | 1.9 Million USD | -142.088% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 77.591% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 95.548% |
| CSL Limited | 18.62 Billion USD | 99.975% |
| Cellectis S.A. | 249.36 Million USD | 98.155% |